LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib|
- Overall response rate (ORR) to LDK378 by investigator assessment [ Time Frame: 6 cycles of 28 days up to 24 weeks ]ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response or partial response (CR+PR) as assessed by investigator
- Duration of response (DOR) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]DOR, calculated as the time from the date of the first documented CR or PR to the first documented progression or death due to underlying cancer, by investigator and BIRC (Blinded Imaging Review Committee)
- Disease control rate (DCR) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]DCR, calculated as the proportion of patients with best overall response of CR, PR, or SD, by investigator and BIRC
- Time to Response (TTR) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]TTR, calculated as the time from first dose of LDK378 to first documented response (CR+PR), by investigator and BIRC
- ORR by BIRC assessment [ Time Frame: 6 cycles of 28 days up to 24 weeks ]ORR (CR+PR) per RECIST 1.1 as assessed by BIRC
- Safety profile [ Time Frame: 6 cycles of 28 days up to 24 weeks ]Adverse events and laboratory abnormalities
- Progression-free survival (PFS) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]PFS, defined as time from first dose of LDK378 to progression or death due to any cause, as assessed by BIRC and investigator assessment
- Overall survival (OS) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]OS, defined as time from first dose of LDK378 to death due to any cause
- Overall intracranial response rate (OIRR) [ Time Frame: 6 cycles of 28 days up to 24 weeks ]OIRR calculated as the ORR (CR+PR) of lesions in the brain for patients who have measureable disease in the brain at baseline
|Study Start Date:||November 2012|
|Study Completion Date:||March 2016|
|Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Oral LDK378 750 mg once daily
Other Name: Oral LDK378 750mg once daily
Hide Detailed Description
This is a single-arm, open-label, multicenter, phase II study in which the efficacy and safety of LDK378 will be evaluated in patients with stage IIIB or IV NSCLC harboring a confirmed ALK rearrangement, defined as 15% or more positive tumor cells as assessed by the FDA-approved FISH test (Abbott Molecular Inc.) using Vysis break-apart probes. If documentation of ALK rearrangement by the FDA-approved FISH test is available, no further ALK test is required for inclusion in the study. If such documentation is not available, a new test to assess ALK status by the FDA-approved Vysis ALK break-apart FISH test should be performed.
Patients must have been pretreated with cytotoxic chemotherapy (1 to 3 prior lines, of which 1 must have been a platinum doublet) and then with crizotinib. Patients may also have received first line treatment with crizotinib followed by cytotoxic chemotherapy and, subsequently, a rechallenge treatment with crizotinib. Patients must have demonstrated progression (regardless of initial response) on the last crizotinib treatment, i.e. the crizotinib regimen received as the last therapy prior to study entry.
The study begins with a screening period to assess eligibility, up to and including 28 days prior to the first dose of LDK378.
The treatment period begins on Day 1 of Cycle 1. All patients will be treated with LDK378, administered orally, at a starting dose of 750 mg. A total of approximately 137 patients will be enrolled in the study. Patients will take LDK378 once daily, at approximately the same time each day. On days when a PK sample is obtained, the patient will take LDK378 during the clinic visit as instructed by the study staff. Treatment with LDK378 will continue until the patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the patient or investigator, starts a new anti-cancer therapy or dies. If the patient experiences RECIST-defined progressive disease (PD) on LDK378 as assessed by the investigator, treatment with the study drug may be continued if, in the judgment of the investigator, there is still evidence of clinical benefit. These patients will be counted as PD for ORR, DOR, DCR and PFS calculations.
Assessments of tumor response and progression will be performed every 8 weeks (i.e. every 2 cycles), starting from the first day of treatment with LDK378. This schedule of tumor assessment must continue regardless of dose interruptions. Tumor assessment should continue until:
- For patients who experience PD as assessed by the investigator, tumor assessments should continue every 8 weeks until LDK378 is permanently discontinued (i.e. if the patient continues treatment with LDK378 after PD, tumor assessments should continue until LDK378 is permanently discontinued).
- For patients who discontinue treatment in the absence of PD, tumor assessments should continue every 8 weeks from the EOT visit until PD is assessed by the investigator.
Tumor evaluations will always cease if the patient starts a new anti-cancer therapy, withdraws consent (unless the patient agrees to continue efficacy assessments in absence of dosing with LDK378), or dies.
All tumor imaging assessments will be submitted for independent radiological assessment of response by a Blinded Independent Review Committee (BIRC).
Clinical and laboratory assessments will be performed.
When the patient discontinues from study treatment an End of Treatment (EOT) visit must be performed as soon as possible and within 7 days of the last dose of LDK378. Patients will be contacted for the safety follow-up 30 days after their last dose of LDK378 to determine if they have experienced any new AEs and/or to follow resolution of ongoing AEs.
Following the end of tumor assessments, the Study Phase Completion Disposition eCRF must be completed. Patients will be contacted every 3 months to obtain information pertaining to survival status until death, loss to follow-up, withdrawal of consent to survival follow-up, or the end of the study. Patients do not need to visit the clinic during the survival follow-up.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01685060
Show 52 Study Locations
|Study Director:||Novartis Pharmaceuticals||Novartis Pharmaceuticals|